Published on: May 21, 2026

CJC-1295: The Long-Acting Growth Hormone Signal

A research-grounded look at how CJC-1295 extends the body’s natural growth hormone pathway, what the evidence actually shows, and what makes it different from other peptides in its class.

Man performing pull-ups on outdoor exercise bar in park

May 21, 2026

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is CJC-1295?

Most peptides in the growth hormone space work fast and fade fast. They send a signal, the body responds, and within hours the peptide is gone. That timing is actually intentional. It mimics the way the body naturally pulses growth hormone throughout the day.

CJC-1295 takes a different approach entirely. It was engineered to stay. And that single design decision is a big part of why it keeps coming up in conversations about weight loss, body composition, recovery, and anti-aging. Not because it is a magic solution for any of those things, but because it works on a system (growth hormone) that touches all of them.

Whether the hype matches the evidence is a more nuanced question.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH (growth hormone-releasing hormone, the body’s natural signal that triggers GH production)), the same natural signal your brain uses to tell the body when to release growth hormone. Like sermorelin, it targets the hypothalamic-pituitary axis, the system responsible for regulating hormone production.¹

But here is the key difference: CJC-1295 has been modified to last much longer in the body. Through a process called DAC (Drug Affinity Complex (a chemical modification that allows the peptide to bind to a blood protein and circulate longer)) binding, the peptide attaches to albumin in the bloodstream, significantly extending its half-life (the time it takes for half of a dose to be cleared from the body) from minutes to several days.² Instead of sending a quick signal and disappearing, CJC-1295 sticks around and keeps signaling.

Fast Facts

FULL NAME	CJC-1295 (also known as DAC:GRF; Drug Affinity Complex: Growth Hormone-Releasing Factor)
CLASS	GHRH analogue (growth hormone-releasing hormone)
PRIMARY ACTION	Long-acting synthetic version of a natural hormone that stimulates the pituitary gland to release growth hormone
ADMINISTRATION	Investigational; swallowed in research settings
HALF-LIFE	8 days (with DAC); ~30 minutes (without DAC)
RESEARCH	Growth hormone deficiency, muscle preservation, body composition, and aging
REGULATORY STATUS	Investigational; not FDA approved; classified as a prohibited substance by WADA (World Anti-Doping Agency)

How Does CJC-1295 Work?

Think of CJC-1295 as a long-acting signal amplifier for growth hormone release. It does not introduce a foreign hormone into the body. Instead, it extends and amplifies the body’s own signaling pathway.

1. Prolonged Stimulation of Growth Hormone

CJC-1295 binds to GHRH receptors in the pituitary gland, stimulating the release of growth hormone. But unlike shorter-acting peptides, it continues to stimulate this pathway over an extended period due to its long half-life. This leads to sustained increases in growth hormone and elevated levels of IGF-1, its primary downstream mediator.² That sustained effect is both its biggest advantage and something that requires careful consideration.

2. Increased IGF-1 and Systemic Effects

As growth hormone levels rise, the liver produces more insulin-like growth factor 1 (IGF-1). IGF-1 plays a major role in muscle growth and repair, fat metabolism, and tissue regeneration.^2,3 Because CJC-1295 keeps GH levels elevated longer than natural pulses, IGF-1 levels may remain elevated for extended periods as well.

3. Altering Natural Hormone Rhythms

Here is where nuance matters. The body naturally releases growth hormone in pulses, not a steady stream. This rhythm helps regulate balance and prevent overstimulation. CJC-1295, especially with DAC, can blur that natural pattern by creating a more sustained signal.^4,1 That does not automatically make it harmful, but it does make it different from peptides that mimic natural pulsatility, and that distinction matters clinically.

What Does the Research Say?

One of the most cited human studies showed that a single dose of CJC-1295 led to sustained elevations in GH and IGF-1 for up to several days.² That is unusual for a peptide in this class, and one reason why it continues to attract significant attention in both clinical and research settings.

THERAPEUTIC AREA	WHAT RESEARCH SUGGESTS	EVIDENCE LEVEL
Growth Hormone Levels	Significant, sustained increases in GH and IGF-1 lasting several days after a single dose	CLINICAL TRIALS
Body Composition	Potential improvements in fat metabolism tied to elevated GH and IGF-1	EARLY CLINICAL
Anti-Aging and Wellness	Theoretical benefits tied to GH signaling; direct long-term outcomes not established	LIMITED DATA
Muscle Recovery	Indirect effects via IGF-1 on tissue repair; strong biological rationale, limited direct evidence	EARLY / INDIRECT

Growth Hormone and Body Composition

Growth hormone plays a well-established role in fat breakdown (lipolysis), preservation of lean muscle, and metabolic regulation. By increasing GH and IGF-1, CJC-1295 may contribute to reduced fat mass and improved body composition over time.^2,4

But here is the thing to keep in mind: most of the direct evidence is based on hormone levels, not long-term physical outcomes. We know it changes the signals. We are still learning how that translates into real-world results over time, particularly in otherwise healthy individuals who are not GH-deficient.

Recovery and Performance

Because GH and IGF-1 are involved in tissue repair, CJC-1295 is often discussed in the context of exercise recovery, injury repair, and performance optimization. There is a strong biological rationale here, given what we know about GH’s role in muscle and connective tissue.³

But the direct clinical evidence in healthy populations is still limited. This is one of those areas where the mechanism is clear, but the outcomes are still catching up to the biology. That is not a reason to dismiss it, but it is a reason to stay grounded in what the evidence actually supports right now.

Safety Profile and What to Know

CJC-1295 has been evaluated in early clinical trials and is generally well-tolerated in controlled settings. Reported side effects may include injection site reactions, headaches, water retention, and flushing.²

Because it increases GH and IGF-1 over extended periods, there are theoretical concerns around prolonged hormone elevation, metabolic effects, and long-term safety, which is still not well established. Another key consideration: CJC-1295 is often discussed in two forms, with DAC and without DAC, which have very different durations and hormonal profiles. That distinction matters when evaluating protocols.

As with most peptides, real-world safety depends heavily on dosing, quality of sourcing, and medical oversight. Working with a licensed healthcare provider who understands the nuances of GH-related therapy is essential.

Important Considerations

Not FDA approved

CJC-1295 has no approved therapeutic indication. It is an investigational compound, and its use outside of clinical research is not sanctioned by regulatory agencies.⁵

Banned in competitive sports

The World Anti-Doping Agency (WADA) classifies CJC-1295 as a prohibited substance. Athletes subject to drug testing should be aware of this.⁵

Long-term safety is not established

While short-term studies show increases in GH and IGF-1, the long-term effects of sustained growth hormone stimulation in healthy adults are not well understood.⁶

Elevated IGF-1 carries potential risks

Sustained high levels of IGF-1 have been linked in some research to increased cell growth. What this means for people using CJC-1295 is not fully known.⁷

Compounding pharmacy concerns

CJC-1295 is sometimes available through compounding pharmacies, but quality and purity are not guaranteed without third-party testing.

Medical supervision is essential

Peptide CJC-1295 is a potent, long-acting (8 hours), and powerful Growth Hormone and should be discussed with a health care provider about indication, frequency, and dosing with concurrent lab follow up studies. Patients should share all peptide types and dosages they are receiving with family members, healthcare providers, and other pertinent contacts – especially when their health shifts or changes unexpectedly.

The Bottom Line

CJC-1295 is one of the more unique peptides in the growth hormone category. Not because it introduces something entirely new, but because it changes the timing of the signal. It amplifies and extends the body’s natural GH pathway, leading to sustained hormonal effects that are both promising and not yet fully understood. The science clearly shows it can increase GH and IGF-1. What is less clear is how that translates into long-term outcomes, especially in otherwise healthy individuals. Like much of peptide therapy, it sits in that middle ground: a strong biological mechanism with an evolving clinical picture.

Scientific References

1. Vance ML. Growth hormone-releasing hormone. Endocrinol Metab Clin North Am. 1992;21(3):631-645.

2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

3. Bowers CY. Growth hormone-releasing peptides and their analogs. Endocr Rev. 1998;19(4):398-425.

4. Modder UI, Achenbach SJ, Amin S, et al. Relation of serum IGF-1 to longitudinal changes in bone and body composition in older men. J Bone Miner Res. 2007;22(6):889-895.

5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.

6. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.

7. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.

© 2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io.

For licensing or reprint inquiries, please contact content@peptidematch.io.